An AI agent built by Jakob Kather's team at TU Dresden's Else Kröner Fresenius Center for Digital Health, called MIRA (Medical Intelligence for Reasoning and Action), achieved 87.8% diagnostic accurac…
Insilico Medicine announced that its AI-discovered drug rentosertib, a treatment for idiopathic pulmonary fibrosis, will begin Phase 3 trials in China, with the first patient dosed on Sept. 10, accord…
A drug designed with artificial intelligence called rentosertib shifted blood protein patterns toward a lower predicted biological age in people with idiopathic pulmonary fibrosis, according to a stud…
An AI-designed drug, rentosertib, developed by Insilico Medicine for idiopathic pulmonary fibrosis, showed signs of reducing biological age in a 12-week phase 2a clinical trial, according to findings …
Insilico Medicine's AI-designed drug rentosertib showed in a 12-week clinical trial that all 42 participants with idiopathic pulmonary fibrosis had reduced predicted ages across six different aging cl…
An experimental AI-designed drug, rentosertib, developed by Insilico Medicine to treat idiopathic pulmonary fibrosis (IPF), appeared to reverse biological-age markers by up to six years in a small hum…
Insilico Medicine co-CEO Feng Ren said the company's experimental fibrosis drug reduced patients' predicted biological age by roughly three years on average, and up to six years on one measure, raisin…
An AI-designed drug, Rentosertib, appeared to make patients biologically younger across six ageing clocks in a small trial of idiopathic pulmonary fibrosis, according to research published in Nature B…
Insilico Medicine's AI-discovered drug rentosertib reduced biological age in a midstage study of 42 patients with chronic lung disease, as measured by six aging clocks, according to an analysis publis…
Insilico Medicine's AI-designed drug rentosertib reduced biological age markers across six AI-powered aging clocks in a 43-patient trial for idiopathic pulmonary fibrosis, results published in Nature …
A study published in Nature Biotechnology reports that Insilico Medicine's AI-generated drug rentosertib reduced biological age markers in 42 patients over a 12-week trial, as measured by six aging cl…
Insilico Medicine's AI-designed drug rentosertib reversed biological aging markers in a 42-patient early trial, with six aging clocks predicting treated patients were up to six years younger biologica…
Early data from a study published in Nature Aging indicates that an A.I.-generated drug candidate, named TAC-101, could slow aging in mice, extending their lifespan by 10%. The research, led by scient…
Insilico Medicine's AI-designed drug rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 pat…
Insilico Medicine's AI platform PandaOmics identified a novel pain target, leading to the discovery of ISM9528, an oral, brain-penetrant, non-opioid candidate that outperformed morphine in preclinical…
Reflect Orbital's plan to launch space mirrors that beam sunlight to Earth could brighten the night sky as much as 10,000 full moons and scatter light over tens of kilometers, according to a new study…
Insilico Medicine named five humans, including CEO Alex Zhavoronkov, as inventors on a patent for a pulmonary fibrosis drug that its generative AI platform proposed, highlighting a US legal rule that …
Insilico Medicine is previewing a Virtual Aging Cell research direction that incorporates biological age into its virtual-cell models, aiming to improve predictions of cellular responses to genetic ed…
Pathos AI, a New York City-based AI-driven drug development company, agreed to license the experimental breast cancer drug JSKN016 from China's Jiangsu Alphamab Biopharmaceutical for an upfront paymen…
Insilico Medicine announced on July 29 that the U.S. FDA granted Fast Track Designation to its AI-designed pan-TEAD inhibitor ISM6331 for adults with unresectable malignant pleural mesothelioma after …